SCHEMBL18095595

SCHEMBL18095595

CC(NC(=O)OCc1ccccc1)C(=O)NC(CCCNC(=O)OC(C)(C)C)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 1/20 0.54
▸ FOLH1 Q04609 2/20 0.54
▸ MAPT P10636 1/20 0.53
▸ CPB1 P15086 1/20 0.53
▸ CPB2 Q96IY4 1/20 0.53
▸ SIRT2 Q8IXJ6 1/20 0.52
▸ SIRT1 Q96EB6 1/20 0.52
▸ CTSK P43235 1/20 0.51
▸ MMP1 P03956 1/20 0.51
▸ MMP3 P08254 1/20 0.51
▸ MMP9 P14780 1/20 0.51
▸ KLK7 P49862 2/20 0.50
▸ KLK5 Q9Y337 2/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ ITGB3 P05106 1/20 0.49
▸ ITGAV P06756 1/20 0.49
▸ TGM2 P21980 1/20 0.49
▸ CAPN1 P07384 1/20 0.48
▸ CAPN2 P17655 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10035709 0.94 SYK (0.54) SYKMAPTCTSKMMP1MMP3
SCHEMBL30134405 0.92 CTSK (0.57) FOLH1MAPTCPB1CPB2CTSK
SCHEMBL4958981 0.92 SYK (0.60) SYKFOLH1MAPTCPB1CPB2
SCHEMBL918813 0.92 SYK (0.60) SYKFOLH1MAPTCPB1CPB2
SCHEMBL1021938 0.92 SYK (0.60) SYKFOLH1MAPTCPB1CPB2
SCHEMBL13599694 0.90 MAPT (0.56) SYKFOLH1MAPTCPB1CPB2
SCHEMBL19971941 0.89 SIRT2 (0.53) SYKMAPTSIRT2SIRT1CTSK
SCHEMBL19971942 0.89 SIRT2 (0.53) SYKMAPTSIRT2SIRT1CTSK
SCHEMBL19971949 0.89 SIRT2 (0.53) SYKMAPTSIRT2SIRT1CTSK
SCHEMBL19971948 0.89 SIRT2 (0.53) SYKMAPTSIRT2SIRT1CTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10858389-B2 Solution phase method for preparing etelcalcetide AMGEN INC. (US) 2020-12-08 — — US disclosed
EP-3274360-B1 SOLUTION PHASE METHOD FOR PREPARING ETELCALCETIDE AMGEN INC (US) 2020-05-06 — — EP disclosed
US-20180079777-A1 SOLUTION PHASE METHOD FOR PREPARING ETELCALCETIDE AMGEN INC. 2018-03-22 — — US disclosed
EP-3274360-A1 SOLUTION PHASE METHOD FOR PREPARING ETELCALCETIDE Amgen Inc. (US) 2018-01-31 — — EP disclosed
WO-2016154580-A1 SOLUTION PHASE METHOD FOR PREPARING ETELCALCETIDE AMGEN INC. (US) 2016-09-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10858389-B2 Solution phase method for preparing etelcalcetide PTH1R, CALCR, SOST SYK 467/4885FOLH1 979/4885MAPT 3828/4885
US-20180079777-A1 SOLUTION PHASE METHOD FOR PREPARING ETELCALCETIDE PTH1R, CALCR, SOST SYK 467/4885FOLH1 979/4885MAPT 3828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback